At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 55 enrolled

Drug / intervention

D-serine +3 moredrug

Likely dose

D-serine 30 mg/kgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00322023

NCT00322023Phase 2Completed

Compare CT.gov

PK/PD Study of Escalating Dose D-serine as Adjunctive Treatment in Schizophrenia

Nathan Kline Institute for Psychiatric Research·interventional·Posted May 4, 2006·Updated Oct 5, 2020

In Brief

A Phase 2 clinical trial evaluating D-serine for Schizophrenia. Completed, enrolled 55 participants across 3 sites.

Detailed Summary

This study will determine whether increasing D-serine within the body will improve negative symptoms and cognitive impairments in people with schizophrenia.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsSchizophrenia

CountriesUnited States

CollaboratorsNational Institute of Mental Health (NIMH)

Timeline

Phase 2CompletedFinished

2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Enrollment StartMar 2006

First PostedMay 2006

Primary CompletionJan 2009

TodayJul 2026

First PostedMay 4, 2006

Enrollment StartMar 1, 2006

Primary CompletionJan 1, 2009

TodayJul 2, 2026

Enrollment to primary: 2.8 yearsPosted 20.2 years ago

Interventions

D-serinedrug

D-serine at following dose levels: 30 mg/kg, 60 mg/kg, and 120 mg/kg. PK/PD studies done at day 1. Medication will be administered as powder dissolved in liquid given in two divided doses daily for 4 weeks.

D-serinedrug